Payment overview · 2025
General Payments
$436.14
11 reported records · 7 companies
Healthcare provider profile · identity verified
Yangjing Lin, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · NEW YORK, NY · NPI 1053085894
Verified facts
What the public records show
CMS Open Payments records show Yangjing Lin, NP received $436.14 in general payments during 2025 across 11 reported records.
Amgen Inc. accounted for 43.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $190.61 | 43.7% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $98.71 | 22.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.69 | 10.7% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $31.21 | 7.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.31 | 6.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.00 | 5.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.61 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $436.14 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $179.33 | 3 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $98.71 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $98.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.69 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $31.21 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.31 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.31 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.31 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $11.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 74 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 199 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
73 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
199 | 54 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
74 | 74 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1444 | 373 |
| Vascepa | Icosapent Ethyl | 1084 | 270 |
| Losartan Potassium | Losartan Potassium | 933 | 237 |
| Amlodipine Besylate | Amlodipine Besylate | 822 | 227 |
| Diclofenac Epolamine | Diclofenac Epolamine | 618 | 195 |
| Metformin Hcl | Metformin Hcl | 532 | 136 |
| Tamsulosin Hcl | Tamsulosin Hcl | 513 | 126 |
| Alendronate Sodium | Alendronate Sodium | 354 | 111 |
| Fluticasone Propionate | Fluticasone Propionate | 310 | 153 |
| Ammonium Lactate | Ammonium Lactate | 303 | 109 |
| Diclofenac Sodium | Diclofenac Sodium | 285 | 124 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 272 | 99 |
| Donepezil Hcl | Donepezil Hcl | 235 | 63 |
| Simvastatin | Simvastatin | 228 | 70 |
| Mometasone Furoate | Mometasone Furoate | 225 | 123 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 222 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 63 |
| Jardiance | Empagliflozin | 199 | 54 |
| Famotidine | Famotidine | 194 | 88 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 184 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 41 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 159 | 65 |
| Montelukast Sodium | Montelukast Sodium | 153 | 40 |
| Omeprazole | Omeprazole | 145 | 80 |
| Bepotastine Besilate | Bepotastine Besilate | 131 | 51 |
| Finasteride | Finasteride | 131 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 61 |
| Rybelsus | Semaglutide | 117 | 29 |
| Januvia | Sitagliptin Phosphate | 110 | 28 |
| Restasis | Cyclosporine | 110 | 31 |
| Clobetasol Propionate | Clobetasol Propionate | 108 | 65 |
| Lisinopril | Lisinopril | 108 | 29 |
| Celecoxib | Celecoxib | 107 | 88 |
| Trazodone Hcl | Trazodone Hcl | 107 | 59 |
| Ibuprofen | Ibuprofen | 101 | 87 |
| Synthroid | Levothyroxine Sodium | 101 | 22 |
| Glipizide Er | Glipizide | 100 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 100 | 57 |
| Vemlidy | Tenofovir Alafenamide | 100 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 24 |
| Atenolol | Atenolol | 94 | 27 |
| Farxiga | Dapagliflozin Propanediol | 90 | 21 |
| Allopurinol | Allopurinol | 82 | 19 |
| Meclizine Hcl | Meclizine Hcl | 82 | 63 |
| Acarbose | Acarbose | 81 | 20 |
| Hydrocortisone | Hydrocortisone | 80 | 63 |
| Ketoconazole | Ketoconazole | 78 | 37 |
| Dexlansoprazole Dr | Dexlansoprazole | 76 | 36 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 74 | 74 |
| Glipizide | Glipizide | 74 | 17 |
| Xarelto | Rivaroxaban | 73 | 21 |
| Azelastine Hcl | Azelastine Hcl | 70 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 23 |
| Ezetimibe | Ezetimibe | 70 | 17 |
| Fenofibrate | Fenofibrate,micronized | 66 | 14 |
| Mupirocin | Mupirocin | 62 | 48 |
| Alcohol Pads | Alcohol Antiseptic Pads | 60 | 41 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 55 | 28 |
| Creon | Lipase/Protease/Amylase | 54 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 54 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 54 | 28 |
| Metformin Hcl Er | Metformin Hcl | 53 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 52 | 18 |
| Loperamide | Loperamide Hcl | 51 | 36 |
| Nexium | Esomeprazole Magnesium | 51 | 13 |
| Procto-Med Hc | Hydrocortisone | 51 | 23 |
| Eliquis | Apixaban | 50 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 49 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 11 |
| Halobetasol Propionate | Halobetasol Propionate | 48 | 26 |
| Gabapentin | Gabapentin | 46 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | suppressed |
| Clotrimazole | Clotrimazole | 43 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 11 |
| Azithromycin | Azithromycin | 40 | 35 |
| Myrbetriq | Mirabegron | 40 | 12 |
| Ursodiol | Ursodiol | 40 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Prednisone | Prednisone | 38 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 12 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 28 |
| Carvedilol | Carvedilol | 35 | suppressed |
| Dutasteride | Dutasteride | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Naproxen | Naproxen | 33 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | 12 |
| Meloxicam | Meloxicam | 29 | 23 |
| Raloxifene Hcl | Raloxifene Hcl | 29 | 13 |
| Tradjenta | Linagliptin | 29 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 17 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Nexletol | Bempedoic Acid | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 15 |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Furosemide | Furosemide | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | 12 |
| Nitroglycerin | Nitroglycerin | 17 | 17 |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 17 | 16 |
| Valsartan | Valsartan | 17 | suppressed |
| Linzess | Linaclotide | 16 | 11 |
| Calcitriol | Calcitriol | 15 | suppressed |
| Edarbi | Azilsartan Medoxomil | 15 | suppressed |
| Leflunomide | Leflunomide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 13 |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Orencia Clickject | Abatacept | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Cyclosporine | Cyclosporine | 11 | 11 |
| Denta 5000 Plus | Fluoride (Sodium) | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $436.14 · 11 records | Amgen Inc. | ABRYSVO, ARISTADA, ARISTADA INITIO, COMIRNATY, Cologuard Collection Kit, EVENITY, INVEGA SUSTENNA, JARDIANCE, PREVNAR 20, PROLIA, REPATHA, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error